Oxodotreotide
Somatostatin Receptor Positive
National Cancer Institute (NCI)protein_peptidePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Somatostatin Receptor Positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LYSINE ITM Solucin GmbH | Phase 1 | CC |
DOTATOC ITM Solucin GmbH | Phase 1 | CC |
ARG ITM Solucin GmbH | Phase 1 | CC |
[212pb]vmt-alpha-net National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Oxodotreotide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →